Doug Cole

Doug Cole joined Flagship Pioneering in 2001. He focuses on life science. At Flagship, Doug has co-founded Ensemble Therapeutics, Foghorn Therapeutics (NASDAQ: FHTX), Inzen Therapeutics, Moderna (NASDAQ: MRNA), Permeon Biologics, Sigilon Therapeutics (NASDAQ: SGTX, acquired by Lilly), and Syros Pharmaceuticals (NASDAQ: SYRS). He has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro (NASDAQ: AVDR, acquired by Glaukos), CombinatoRx (NASDAQ: ZLCS), Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics (NASDAQ: DNLI), Editas (NASDAQ: EDIT), Quanterix Corporation (NASDAQ: QTRX), Receptos (NASDAQ: RCPT, acquired by Celgene), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Torque. He currently serves on the board of directors of Foghorn Therapeutics, KSQ Therapeutics, Harbinger Health, Repertoire Immune Medicines, Sana Biotechnology (NASDAQ: SANA), and Sonata Therapeutics. He formerly served on the board of directors of Avedro, AVEO Oncology (NASDAQ: AVEO), CombinatoRx, Concert Pharmaceuticals, CGI, Denali Therapeutics, Moderna, Morphotek (acquired by Eisai Pharmaceuticals), Receptos, Resolvyx, Selecta (NASDAQ: SELB), Seventh Sense, Sigilon Therapeutics, Taris (acquired by JNJ), and Tetraphase. Before joining Flagship, Doug was instructor in neurology at Harvard Medical School and assistant in neurology at the Massachusetts General Hospital; medical director at Cytotherapeutics, in Providence, Rhode Island; and program executive at Vertex Pharmaceuticals, Inc., in Cambridge, Mass. He holds an A.B. magna cum laude with high distinction in English from Dartmouth College, where he was a senior fellow and a member of Phi Beta Kappa, and an M.D. from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, and in neurology at the Massachusetts General Hospital in Boston, Mass. Doug is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.